menu
    • menu

    Find Cidofovir manufacturers, exporters & distributors on PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Aurigene is a global leader in accelerating drug innovation through discovery, development & manufacturing.

    Virtual Booth

    Contact Supplier

    Midas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-06

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Synopsis

    Related ProductsRelated Products

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    5

    API Suppliers

    API Suppliers

    4

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    1

    EU WC

    EU WC

    0

    KDMF

    KDMF

    8

    NDC API

    NDC API

    0

    VMF

    NDC API

    3

    Listed Suppliers

    Other Suppliers

    API REF. PRICE (USD/KG)

    $
    $ 169,674

    MARKET PLACE

    1

    API

    5

    FDF

    3INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    6

    FDF Dossiers

    FDF Dossiers

    3

    FDA Orange Book

    FDA (Orange Book)

    2

    Europe

    Europe

    1

    Canada

    Canada

    0

    Australia

    Australia

    0

    South Africa

    South Africa

    0

    Listed Dossiers

    Listed Dossiers

    0 DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    3

    USP

    0

    JP

    4

    Others

    PATENTS & EXCLUSIVITIES

    0

    US Patents

    0

    US Exclusivities

    0

    Health Canada Patents

    DIGITAL CONTENT

    0

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    8

    News #PharmaBuzz

    GLOBAL SALES INFORMATION

    US Medicaid

    115,208

    Annual Reports

    NA

    Finished Drug Prices

    Listed Dossiers

    1 RELATED EXCIPIENT COMPANIES

    1EXCIPIENTS BY APPLICATIONS

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 113852-37-2, Vistide, Hpmpc, Cidofovir anhydrous, (s)-hpmpc, Gs-504
    Molecular Formula
    C8H14N3O6P
    Molecular Weight
    279.19  g/mol
    InChI Key
    VWFCHDSQECPREK-LURJTMIESA-N
    FDA UNII
    768M1V522C
    Cidofovir
    An acyclic nucleoside phosphonate that acts as a competitive inhibitor of viral DNA polymerases. It is used in the treatment of RETINITIS caused by CYTOMEGALOVIRUS INFECTIONS and may also be useful for treating HERPESVIRUS INFECTIONS.
    Cidofovir anhydrous is a Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor. The mechanism of action of cidofovir anhydrous is as a DNA Polymerase Inhibitor.
    1 2D Structure

    Cidofovir

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    [(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid
    2.1.2 InChI
    InChI=1S/C8H14N3O6P/c9-7-1-2-11(8(13)10-7)3-6(4-12)17-5-18(14,15)16/h1-2,6,12H,3-5H2,(H2,9,10,13)(H2,14,15,16)/t6-/m0/s1
    2.1.3 InChI Key
    VWFCHDSQECPREK-LURJTMIESA-N
    2.1.4 Canonical SMILES
    C1=CN(C(=O)N=C1N)CC(CO)OCP(=O)(O)O
    2.1.5 Isomeric SMILES
    C1=CN(C(=O)N=C1N)C[C@@H](CO)OCP(=O)(O)O
    2.2 Other Identifiers
    2.2.1 UNII
    768M1V522C
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 1-((3-hydroxy-2-phosphonylmethoxy)propyl)cytosine

    2. 1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine

    3. Cidofovir Anhydrous

    4. Cidofovir Sodium

    5. Cidofovir, (+-)-isomer

    6. Cidofovir, (r)-isomer

    7. Cidofovir, Sodium Salt

    8. Gs 504

    9. Gs-504

    10. Gs504

    11. Hpmpc

    12. Vistide

    2.3.2 Depositor-Supplied Synonyms

    1. 113852-37-2

    2. Vistide

    3. Hpmpc

    4. Cidofovir Anhydrous

    5. (s)-hpmpc

    6. Gs-504

    7. Anhydrous Cidofovir

    8. Cidofovir [inn]

    9. Cidofovir (vistide)

    10. Cidofovir Hydrate

    11. Gs 0504

    12. (s)-1-(3-hydroxy-2-phosphonomethoxypropyl)cytosine

    13. Cdv

    14. [1-(4-amino-2-oxo-pyrimidin-1-yl)-3-hydroxy-propan-2-yl]oxymethylphosphonic Acid

    15. Gs-0504

    16. (s)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine

    17. (s)-(((1-(4-amino-2-oxopyrimidin-1(2h)-yl)-3-hydroxypropan-2-yl)oxy)methyl)phosphonic Acid

    18. Chebi:3696

    19. Hpmpc Dihydrate

    20. ({[(2s)-1-(4-amino-2-oxopyrimidin-1(2h)-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic Acid

    21. (s)-1-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine

    22. 768m1v522c

    23. Nsc-742135

    24. Ncgc00184994-01

    25. Phosphonic Acid, ((2-(4-amino-2-oxo-1(2h)-pyrimidinyl)-1-(hydroxymethyl)ethoxy)methyl)-, (s)-

    26. 1-(s)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine

    27. 1-[(s)-3-hydroxy-2-(phosphonomethoxy)propyl]cytosine

    28. Cidofovir (anhydrous)

    29. Cidofovir Hydrate (1:2)

    30. Cidofovirum

    31. Forvade

    32. (s)-(3-(4-amino-2-oxopyrimidin-1(2h)-yl)-1-hydroxypropan-2-yloxy)methylphosphonic Acid

    33. [(s)-2-(4-amino-2-oxo-2h-pyrimidin-1-yl)-1-hydroxymethyl-ethoxymethyl]-phosphonic Acid

    34. ({[(2s)-1-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic Acid

    35. Hsdb 7115

    36. Gs504

    37. 1-((s)-3-hydroxy-2-(phosphonomethoxy)propyl)cytosine

    38. Cidofovir Gel

    39. Unii-768m1v522c

    40. Cidofovir,vistide

    41. [[(s)-2-(4-amino-2-oxo-1(2h)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]phosphonic Acid

    42. Cidofovir(vistide)

    43. (((s)-2-(4-amino-2-oxo-1(2h)-pyrimidinyl)-1-(hydroxymethyl)ethoxy)methyl)phosphonic Acid

    44. Forvade (tm)

    45. Cidofovir [mi]

    46. Cidofovir [hsdb]

    47. Chembl152

    48. Cidofovir [who-dd]

    49. Cidofovir Anhydrous- Bio-x

    50. Schembl3948

    51. Dsstox_cid_23734

    52. Dsstox_rid_80069

    53. Dsstox_gsid_43734

    54. (2s)-3-hydroxy-2-phosphonylmethoxypropyl-cytosine

    55. Mls003915629

    56. (s)-1-[3-hydroxy-2-(phosphonylmethoxy)-propyl]cytosine

    57. Dtxsid3043734

    58. Bdbm31915

    59. 1-[(s)-3-hydroxy-2-(phosphonomethoxy)propyl]-cytosine Dihydrate

    60. Bcp03734

    61. Ex-a4209

    62. Zinc1530600

    63. Tox21_112994

    64. Mfcd00866936

    65. Nsc742135

    66. S1516

    67. Akos005145721

    68. Akos015854828

    69. Ac-1666

    70. Bcp9000528

    71. Ccg-267235

    72. Cs-1669

    73. Db00369

    74. Gs-6438

    75. (s)-2-(4-amino-2-oxo-1(2h)-pyrimidinyl-1-(hydroxymethyl)ethoxy)methyl Phosphonic Acid

    76. [(1s)-1-[(4-amino-2-oxo-pyrimidin-1-yl)methyl]-2-hydroxy-ethoxy]methylphosphonic Acid

    77. Ncgc00184994-02

    78. Ncgc00184994-03

    79. Bc164304

    80. Hy-17438

    81. Smr002544687

    82. Bcp0726000147

    83. Cas-113852-37-2

    84. Ab01566823_01

    85. 394c661

    86. Q423445

    87. Sr-01000931969

    88. J-502695

    89. Sr-01000931969-2

    90. (s)-(((1-(4-amino-2-oxopyrimidin-1(2h)-yl)-3-hydroxypropan-2-yl)oxy)methyl)phosphonicacid

    91. ({[(s)-1-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic Acid

    92. L8p

    93. Phosphonic Acid, [[(1s)-2-(4-amino-2-oxo-1(2h)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]-

    94. Phosphonic Acid,[[(1s)-2-(4-amino-2-oxo-1(2h)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]-

    2.4 Create Date
    2005-06-24
    3 Chemical and Physical Properties
    Molecular Weight 279.19 g/mol
    Molecular Formula C8H14N3O6P
    XLogP3-3.6
    Hydrogen Bond Donor Count4
    Hydrogen Bond Acceptor Count6
    Rotatable Bond Count6
    Exact Mass279.06202217 g/mol
    Monoisotopic Mass279.06202217 g/mol
    Topological Polar Surface Area146 Ų
    Heavy Atom Count18
    Formal Charge0
    Complexity417
    Isotope Atom Count0
    Defined Atom Stereocenter Count1
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 4  
    Drug NameCidofovir
    PubMed HealthCidofovir (Injection)
    Drug ClassesAntiviral
    Drug LabelThe chemical name of cidofovir is 1-[(S)-3-hydroxy-2-(phosphonomethoxy)propyl]cytosine dihydrate (HPMPC), with the molecular formula of C8H14N3O6P2H2O and a molecular weight of 315.22 (279.19 for anhydrous). The chemical structure is:Cidofovir is...
    Active IngredientCidofovir
    Dosage FormInjectable
    RouteInjection
    Strengtheq 75mg base/ml
    Market StatusPrescription
    CompanyEmcure Pharms; Mylan Institutional

    2 of 4  
    Drug NameVistide
    PubMed HealthCidofovir (Injection)
    Drug ClassesAntiviral
    Drug LabelVISTIDE is the brand name for cidofovir injection. The chemical name of cidofovir is 1-[(S)-3-hydroxy-2-(phosphonomethoxy)propyl]cytosine dihydrate (HPMPC), with the molecular formula of C8H14N3O6P2H2O and a molecular weight of 315.22 (279.19 fo...
    Active IngredientCidofovir
    Dosage FormInjectable
    RouteInjection
    Strengtheq 75mg base/ml
    Market StatusPrescription
    CompanyGilead Sciences

    3 of 4  
    Drug NameCidofovir
    PubMed HealthCidofovir (Injection)
    Drug ClassesAntiviral
    Drug LabelThe chemical name of cidofovir is 1-[(S)-3-hydroxy-2-(phosphonomethoxy)propyl]cytosine dihydrate (HPMPC), with the molecular formula of C8H14N3O6P2H2O and a molecular weight of 315.22 (279.19 for anhydrous). The chemical structure is:Cidofovir is...
    Active IngredientCidofovir
    Dosage FormInjectable
    RouteInjection
    Strengtheq 75mg base/ml
    Market StatusPrescription
    CompanyEmcure Pharms; Mylan Institutional

    4 of 4  
    Drug NameVistide
    PubMed HealthCidofovir (Injection)
    Drug ClassesAntiviral
    Drug LabelVISTIDE is the brand name for cidofovir injection. The chemical name of cidofovir is 1-[(S)-3-hydroxy-2-(phosphonomethoxy)propyl]cytosine dihydrate (HPMPC), with the molecular formula of C8H14N3O6P2H2O and a molecular weight of 315.22 (279.19 fo...
    Active IngredientCidofovir
    Dosage FormInjectable
    RouteInjection
    Strengtheq 75mg base/ml
    Market StatusPrescription
    CompanyGilead Sciences

    4.2 Therapeutic Uses

    Cidofovir is used for the treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS).

    McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 2003. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2003 (Plus Supplements)., p. 538

    Cidofovir has been used for the management of acyclovir-resistant herpes simplex virus (HSV-1 and HSV-2) infections in immunocompromised patients.

    McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 2003. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2003 (Plus Supplements)., p. 539

    The role, if any, of cidofovir in the treatment of smallpox remains to be determined. Cidofovir is active in vitro against poxviruses, including variola virus (the causative agent of smallpox) and has in vivo activity in mice against cowpox and vaccinia virus. Although limited in vitro and in vivo data suggest that cidofovir might prove useful in preventing smallpox infection if administered within 1-2 days after exposure, there currently is no evidence that the antiviral would be more effective than vaccination in this early period.

    McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 2003. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2003 (Plus Supplements)., p. 539

    Topical cidofovir gel eliminates virus shedding and lesions in some HIV-infected patients with acyclovir-resistant mucocutaneous HSV infections and has been use in treating anogenital warts and molluscum contagiosum in immunocompromised patients and cervical intraepithelial neoplasia in women. Intralesional cidofovir induces remission in adults or chlidren with respiratory papillomatosis.

    Hardman, J.G., L.E. Limbird, P.B., A.G. Gilman. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill, 2001., p. 1322

    For more Therapeutic Uses (Complete) data for CIDOFOVIR (15 total), please visit the HSDB record page.

    4.3 Drug Warning

    Placement of a ganciclovir ocular implant in patients receiving IV cidofovir has resulted in profound hypotomy in some patients, and some clinicians suggest that IV cidofovir not be administered within one month before or after placement of a ganciclovir ocular implant.

    McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 2003. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2003 (Plus Supplements)., p. 539

    .... Because evidence from clinical trials indicates that previous exposure to foscarnet may increase the risk of cidofovir-related nephrotoxicity, patients treated previously with foscarnet should receive cidofovir only when the potential benefits exceed the possible risks.

    McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 2003. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2003 (Plus Supplements)., p. 539

    Patients should be advised that cidofovir therapy is not curative, and that progression of their retinitis is possible during or following therapy with the drug.

    McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 2003. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2003 (Plus Supplements)., p. 538

    Safety and efficacy of cidofovir in geriatric patients older than 60 years of age have not been established. Because geriatric patients frequently have reduced glomerular filtration, particular attention should be paid to monitoring renal function prior to and during cidofovir therapy in this age group, and doses of the drug should be modified in response to changes in renal function that occur during therapy.

    McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 2003. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2003 (Plus Supplements)., p. 539

    For more Drug Warnings (Complete) data for CIDOFOVIR (20 total), please visit the HSDB record page.

    4.4 Drug Indication

    For the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS)

    FDA Label

    Vistide is indicated for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome (AIDS) and without renal dysfunction. Vistide should be used only when other agents are considered unsuitable.

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    Cidofovir is a new anti-viral drug. It is classified as a nucleotide analogue and is active against herpes cytomegalovirus (CMV) retinitis infection. Most adults are infected with CMV. Cidofovir suppresses cytomegalovirus (CMV) replication by selective inhibition of viral DNA synthesis.

    5.2 MeSH Pharmacological Classification

    Antiviral Agents

    Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)

    Enzyme Inhibitors

    Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)

    5.3 FDA Pharmacological Classification
    5.3.1 Active Moiety
    CIDOFOVIR ANHYDROUS
    5.3.2 FDA UNII
    768M1V522C
    5.3.3 Pharmacological Classes
    DNA Polymerase Inhibitors [MoA]; Nucleoside Analog [EXT]; Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC]
    5.4 ATC Code

    J05AB12

    J - Antiinfectives for systemic use

    J05 - Antivirals for systemic use

    J05A - Direct acting antivirals

    J05AB - Nucleosides and nucleotides excl. reverse transcriptase inhibitors

    J05AB12 - Cidofovir

    5.5 Absorption, Distribution and Excretion

    Absorption

    100%

    Volume of Distribution

    537 126 mL/kg [VISTIDE ADMINISTERED WITHOUT PROBENECID]

    410 102 mL/kg [VISTIDE ADMINISTERED WITH PROBENECID]

    Clearance

    179 +/- 23.1 mL/min/1.73 m2 [WITHOUT PROBENECID]

    148 +/- 38.8 mL/min/1.73 m2 [WITH PROBENECID]

    Volume of distribution is 537 ml/kg without concurrent probenecid administration and 410 ml/kg with concurrent probenecid administration.

    MICROMEDEX Thomson Health Care. USPDI - Drug Information for the Health Care Professional. 22nd ed. Volume 1. MICROMEDEX Thomson Health Care, Greenwood Village, CO. 2002. Content Reviewed and Approved by the U.S. Pharmacopeial Convention, Inc., p. 879

    Concentrations of cidofovir were undetectable 15 minutes after the end of a 1 hour infusion in one patient who had a corresponding serum concentration of 8.7 ug/mL.

    MICROMEDEX Thomson Health Care. USPDI - Drug Information for the Health Care Professional. 22nd ed. Volume 1. MICROMEDEX Thomson Health Care, Greenwood Village, CO. 2002. Content Reviewed and Approved by the U.S. Pharmacopeial Convention, Inc., p. 879

    Renal (without concurrent probenecid administration): Approximately 80 to 100% of an administered cidofovir dose was recovered unchanged in the urine within 24 hours.

    MICROMEDEX Thomson Health Care. USPDI - Drug Information for the Health Care Professional. 22nd ed. Volume 1. MICROMEDEX Thomson Health Care, Greenwood Village, CO. 2002. Content Reviewed and Approved by the U.S. Pharmacopeial Convention, Inc., p. 879

    Cidofovir is dianionic at physiological pH and have low oral bioavailability in animals and humans. After intravenous administration to HIV-infected patients, the pharmacokinetics of /cidofovir is/ independent of dose and are consistent with preclinical data. Systemic exposure is proportional to the intravenous dose and /the drug is cleared/ by the kidney and excreted extensively as unchanged drug in the urine. Intracellular activation of a small fraction (< 10%) of the dose by cellular kinases leads to prolonged antiviral effects that are not easily predicted from conventional pharmacokinetic studies. The observed rate of elimination of cidofovir ... from the serum may not reflect the true duration of action of these drugs, since the antiviral effect is dependent on concentrations of the active phosphorylated metabolites that are present within cells. For /cidofovir/, > 90% of an iv dose is recovered unchanged in the urine over 24 hours.

    PMID:10092959 Cundy KC; Clin Pharmacokinet 36 (2): 127-43 (1999)

    This study was undertaken to evaluate the intravitreal and plasma concentrations of cidofovir (HPMPC) after intravitreal and intravenous administration in AIDS patients with cytomegalovirus retinitis. Cohort series; undiluted vitreous and blood were collected from 9 patients at the time of pars plana vitrectomy. Vitreous samples from 9 eyes of 9 patients and plasma samples from 4 patients were assayed with high-performance liquid chromatography to determine cidofovir levels. The only eye that had a detectable vitreous concentration (673.7 ng/ml) was injected with 20 microg 24 hours prior to the surgery. The remaining samples including plasma were below the detection point of the assay (100 ng/ml) and were injected between 5 and 40 days prior to sampling. The intravitreal concentration of cidofovir in humans is consistent with pharmacokinetics data in laboratory animals, and suggests that the long duration of antiviral effect (1-3 months) in clinical trials is due to a prolonged intracellular half-life in retinal tissue.

    PMID:9572540 Taskintuna I et al; J Ocul Pharmacol Ther 14 (2): 147-51 (1998)

    5.6 Metabolism/Metabolites

    Cidofovir is converted via cellular enzymes to the pharmacologically active diphosphate metabolite ... .

    McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 2003. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2003 (Plus Supplements)., p. 540

    This study was designed to evaluate the intraocular distribution and metabolism of the antiviral nucleotide analogs cidofovir and cyclic 1-[(S)-3-hydroxy-2-(phosphonomethoxy) propyl]cytosine (HPMPC) in New Zealand white rabbits following intravitreal administration. ...Male rabbits received either 14C-cidofovir or 14C-cyclic HPMPC by intravitreal injection into both eyes (50 micrograms/eye, 11 microCi/eye). Two animals/group were sacrificed at 24, 48, 72 or 240 hr post-dose. Ocular tissues, kidney and liver were oxidized to determine total radioactivity and metabolites were determined by HPLC. ...At 24 hr post-dose, total radioactivity was 9.96 and 5.18 micrograms-equiv/g for cidofovir and cyclic HPMPC, respectively, in vitreous and 20.9 and 3.54 micrograms-equiv/g, respectively, in retina. Although the initial vitreal clearance was 2-fold faster for the cyclic analog, the estimated terminal elimination half-lives in vitreous (42 hr) and in retina (66-77 hr) were similar for both drugs. By 240 hr post-dose, radioactivity in all ocular tissues was approx ten-fold higher for cidofovir. Radioactivity in vitreous at 240 hr after intravitreal dosing with either drug contained cidofovir, cyclic HPMPC and cidofovir-phosphocholine. ...The long retinal half-life observed presumably reflects formation of phosphorylated cidofovir within retinal cells. Cidofovir achieved a ten-fold higher level of phosphorylated drug in retina than cyclic HPMPC. Therefore, intravitreal cidofovir may be expected to suppress progression of retinitis for a longer period than an equivalent intravitreal dose of cyclic HPMPC. The intravitreal half-life of cidofovir was 20-fold longer than that of ganciclovir in the same animal model.

    PMID:8670758 Cundy KC et al; Curr Eye Res 15 (5): 569-76 (1996)

    Pyrimidine nucleoside monophosphate kinase converts cidofovir to cidofovir monophosphate, which is further converted to the diphosphate and cidofovir phosphate-choline via other cellular enzymes.

    McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 2003. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2003 (Plus Supplements)., p. 540

    5.7 Biological Half-Life

    2.4 to 3.2 hours

    ...Male rabbits received either 14C-cidofovir ...by intravitreal injection into both eyes (50 micrograms/eye...). ...The estimated terminal elimination half-lives /were/ in vitreous (42 hr) and in retina (66-77 hr)... .

    PMID:8670758 Cundy KC et al; Curr Eye Res 15 (5): 569-76 (1996)

    ...Levels of cidofovir in serum following iv infusion were dose proportional over the dose range of 1.0-10.0 mg/kg bw and declined biexponentially with an overall mean +/- standard deviation terminal half-life of 2.6 +/- 1.2 hr (n=25).

    PMID:7574510 Full text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC162721 Cundy KC et al; Antimicrob Agents Chemother 39 (6): 1247-52 (1995)

    5.8 Mechanism of Action

    Cidofovir acts through the selective inhibition of viral DNA polymerase.Biochemical data support selective inhibition of CMV DNA polymerase by cidofovir diphosphate, the active intracellular metabolite of cidofovir. Cidofovir diphosphate inhibits herpesvirus polymerases at concentrations that are 8- to 600-fold lower than those needed to inhibit human cellular DNA polymerase alpha, beta, and gamma(1,2,3). Incorporation of cidofovir into the growing viral DNA chain results in reductions in the rate of viral DNA synthesis.

    Cidofovir diphosphate exerts its antiviral effect by interfering with DNA synthesis and inhibiting viral replication. The inhibitory activity of cidofovir diphosphate is highly selective because of its greater affinity for viral DNA polymerases than for human DNA polymerases. /Cidofovir diphosphate/

    McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 2003. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2003 (Plus Supplements)., p. 540

    Pyrimidine nucleoside monophosphate kinase converts cidofovir to cidofovir monophosphate, which is further converted to the diphosphate and cidofovir phosphate-choline via other cellular enzymes. Cidofovir diphosphate stop replication of viral DNA by competitive inhibition of viral DNA polymerase, incorporation and termination of the growing viral DNA chain, and inactivation of the viral DNA polymerase. /Cidofovir diphosphate/

    McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 2003. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2003 (Plus Supplements)., p. 540

    Cidofovir /is an/ ... acyclic phosphonate analog of deoxynucleoside monophosphate. /This cmpd/ undergoes intracellular activation to form diphosphates that are potent inhibitors of viral DNA polymerases. Cidofovir has broad spectrum antiviral activity against herpesviruses, papillomaviruses and poxviruses.

    PMID:10092959 Cundy KC; Clin Pharmacokinet 36 (2): 127-43 (1999)

    API Reference Price

    read-more
    read-more
    [{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1657045800,"product":"CIDOFOVIR (QTY: 1 X 0.15 GMS, PRICE: USD 69.92)(FOC)","address":"P.NO. D6 & D8, SY.NO. 234\/2,234\/3, ,235\/2 & 542\/2, IKP KNOWLEDGE PARK,","city":"TURKAPALLY-V SHAMIRPET HYDERABAD,TE","supplier":"UNITED PHARMACOPEIAL CONVENTION","supplierCountry":"ITALY","foreign_port":"NA","customer":"UNITED STATES PHARMACOPEIA - INDIA PRIVATE LIMITED","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"0.00015","unit":"KGS","unitRateFc":"466133.3","totalValueFC":"72.2","currency":"USD","unitRateINR":"38283933.3","date":"06-Jul-2022","totalValueINR":"5742.59","totalValueInUsd":"72.2","indian_port":"HYDERABAD AIR","hs_no":"29335990","bill_no":"9439771","productDescription":"API","marketType":"REGULATED MARKET","country":"ITALY","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"P.NO. D6 & D8, SY.NO. 234\/2,234\/3, ,235\/2 & 542\/2, IKP KNOWLEDGE PARK,"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1657045800,"product":"CIDOFOVIR (QTY: 2 X 0.05 GMS, PRICE: USD 29.34\/EACH)(FOC)","address":"P.NO. D6 & D8, SY.NO. 234\/2,234\/3, ,235\/2 & 542\/2, IKP KNOWLEDGE PARK,","city":"TURKAPALLY-V SHAMIRPET HYDERABAD,TE","supplier":"UNITED PHARMACOPEIAL CONVENTION","supplierCountry":"ITALY","foreign_port":"NA","customer":"UNITED STATES PHARMACOPEIA - INDIA PRIVATE LIMITED","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"0.0001","unit":"KGS","unitRateFc":"586800","totalValueFC":"60.6","currency":"USD","unitRateINR":"48194400","date":"06-Jul-2022","totalValueINR":"4819.44","totalValueInUsd":"60.6","indian_port":"HYDERABAD AIR","hs_no":"29335990","bill_no":"9439771","productDescription":"API","marketType":"REGULATED MARKET","country":"ITALY","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"P.NO. D6 & D8, SY.NO. 234\/2,234\/3, ,235\/2 & 542\/2, IKP KNOWLEDGE PARK,"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1657045800,"product":"CIDOFOVIR (QTY: 2 X 100 MG, PRICE: USD 582\/EACH)(FOC)","address":"P.NO. D6 & D8, SY.NO. 234\/2,234\/3, ,235\/2 & 542\/2, IKP KNOWLEDGE PARK,","city":"TURKAPALLY-V SHAMIRPET HYDERABAD,TE","supplier":"UNITED PHARMACOPEIAL CONVENTION","supplierCountry":"ITALY","foreign_port":"NA","customer":"UNITED STATES PHARMACOPEIA - INDIA PRIVATE LIMITED","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"0.0002","unit":"KGS","unitRateFc":"5820000","totalValueFC":"1202.3","currency":"USD","unitRateINR":"478001250","date":"06-Jul-2022","totalValueINR":"95600.25","totalValueInUsd":"1202.3","indian_port":"HYDERABAD AIR","hs_no":"29335990","bill_no":"9439771","productDescription":"API","marketType":"REGULATED MARKET","country":"ITALY","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"P.NO. D6 & D8, SY.NO. 234\/2,234\/3, ,235\/2 & 542\/2, IKP KNOWLEDGE PARK,"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1722450600,"product":"CIDOFOVIR RELATED COMPOUND A (QTY: 1 X 15MG, VALUE USD: 564)(FOC)","address":"P.NO. D6 D8, SY.NO. 234\/2,234\/3,","city":"TURKAPALLY(V),SHAMEERPET, HYDERABAD","supplier":"USP","supplierCountry":"INDIA","foreign_port":"WASHINGTON, DULLES I","customer":"UNITED STATES PHARMACOPEIA - INDIA PRIVATE LIMITED","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"0.000015","unit":"KGS","unitRateFc":"37600000","totalValueFC":"574.9","currency":"USD","unitRateINR":"3214844667","date":"01-Aug-2024","totalValueINR":"48222.67","totalValueInUsd":"574.9","indian_port":"Hyderabad Air","hs_no":"29335990","bill_no":"4827338","productDescription":"Re-Import","marketType":"REGULATED MARKET","country":"INDIA","selfForZScoreResived":"Pharma Grade","supplierPort":"WASHINGTON, DULLES I","supplierAddress":"7135 ENGLISH MUFFIN WAY FREDERICK,MD 21704 USA Frederick, , United States United States","customerAddress":"P.NO. D6 D8, SY.NO. 234\/2,234\/3,"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1722450600,"product":"CIDOFOVIR RELATED COMPOUND B (QTY: 3 X 15MG, VALUE USD: 564\/EACH) (FOC)","address":"P.NO. D6 D8, SY.NO. 234\/2,234\/3,","city":"TURKAPALLY(V),SHAMEERPET, HYDERABAD","supplier":"USP","supplierCountry":"INDIA","foreign_port":"WASHINGTON, DULLES I","customer":"UNITED STATES PHARMACOPEIA - INDIA PRIVATE LIMITED","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"0.000045","unit":"KGS","unitRateFc":"37600000","totalValueFC":"1724.7","currency":"USD","unitRateINR":"3214844667","date":"01-Aug-2024","totalValueINR":"144668.01","totalValueInUsd":"1724.7","indian_port":"Hyderabad Air","hs_no":"29335990","bill_no":"4827338","productDescription":"Re-Import","marketType":"REGULATED MARKET","country":"INDIA","selfForZScoreResived":"Pharma Grade","supplierPort":"WASHINGTON, DULLES I","supplierAddress":"7135 ENGLISH MUFFIN WAY FREDERICK,MD 21704 USA Frederick, , United States United States","customerAddress":"P.NO. D6 D8, SY.NO. 234\/2,234\/3,"}]
    06-Jul-2022
    01-Aug-2024
    KGS
    overview
    Loading...

    Average Price (USD/KGS)

    Number of Transactions

    Total Quantity (KGS)

    Total Value (USD)

    Quantity (KGS) & Unit rate (USD/KGS) over time

    API Imports and Exports

    Importing Country Total Quantity
    (KGS)    		 Average Price
    (USD/KGS)    		 Number of Transactions

    Upgrade, download data, analyse, strategize, subscribe with us contact

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    USP

    read-more
    read-more

    ABOUT THIS PAGE

    Cidofovir Manufacturers

    A Cidofovir manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cidofovir, including repackagers and relabelers. The FDA regulates Cidofovir manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cidofovir API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

    click here to find a list of Cidofovir manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

    Cidofovir Suppliers

    A Cidofovir supplier is an individual or a company that provides Cidofovir active pharmaceutical ingredient (API) or Cidofovir finished formulations upon request. The Cidofovir suppliers may include Cidofovir API manufacturers, exporters, distributors and traders.

    click here to find a list of Cidofovir suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

    Cidofovir USDMF

    A Cidofovir DMF (Drug Master File) is a document detailing the whole manufacturing process of Cidofovir active pharmaceutical ingredient (API) in detail. Different forms of Cidofovir DMFs exist exist since differing nations have different regulations, such as Cidofovir USDMF, ASMF (EDMF), JDMF, CDMF, etc.

    A Cidofovir DMF submitted to regulatory agencies in the US is known as a USDMF. Cidofovir USDMF includes data on Cidofovir's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Cidofovir USDMF is kept confidential to protect the manufacturer’s intellectual property.

    click here to find a list of Cidofovir suppliers with USDMF on PharmaCompass.

    Cidofovir WC

    A Cidofovir written confirmation (Cidofovir WC) is an official document issued by a regulatory agency to a Cidofovir manufacturer, verifying that the manufacturing facility of a Cidofovir active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Cidofovir APIs or Cidofovir finished pharmaceutical products to another nation, regulatory agencies frequently require a Cidofovir WC (written confirmation) as part of the regulatory process.

    click here to find a list of Cidofovir suppliers with Written Confirmation (WC) on PharmaCompass.

    Cidofovir NDC

    National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Cidofovir as an active pharmaceutical ingredient (API).

    Finished drug products

    The FDA updates the NDC directory daily. The NDC numbers for Cidofovir API and other APIs are published in this directory by the FDA.

    Unfinished drugs

    The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

    Pharmaceutical companies that manufacture Cidofovir as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

    Compounded drug products

    The NDC directory also contains data on finished compounded human drug products that contain Cidofovir and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Cidofovir NDC to their finished compounded human drug products, they may choose to do so.

    click here to find a list of Cidofovir suppliers with NDC on PharmaCompass.

    Cidofovir GMP

    Cidofovir Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

    GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

    PharmaCompass offers a list of Cidofovir GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cidofovir GMP manufacturer or Cidofovir GMP API supplier for your needs.

    Cidofovir CoA

    A Cidofovir CoA (Certificate of Analysis) is a formal document that attests to Cidofovir's compliance with Cidofovir specifications and serves as a tool for batch-level quality control.

    Cidofovir CoA mostly includes findings from lab analyses of a specific batch. For each Cidofovir CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

    Cidofovir may be tested according to a variety of international standards, such as European Pharmacopoeia (Cidofovir EP), Cidofovir JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cidofovir USP).

    Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
    For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search